(Reuters) Activist investor William Ackman’s Pershing Square PHS.AS and Valeant Pharmaceuticals (VRX.TO) on Friday decided to pay $290 million to settle a lawsuit that accused them of insider trading before bidding for Allergan Plc (AGN.N) in 2014. Pershing Square said it decided to raise its share of the settlement to 66.8 percent, or $193.75 million, in a bid to quickly wind up the litigation, which it claimed had “no merit”.
Pershing Square, Valeant Arrive at Settlement Split For Allergan Lawsuit
This entry was posted in Syndicated. Bookmark the permalink.
